在患有HER2和HER3突变癌症的患者中抑制HER激酶
David M Hyman1, Sarina A Piha-Paul2, Helen Won1
1Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Nature
|February 9, 2018
概括
这项研究使用药物内拉替尼对各种癌症的HER2和HER3突变进行了研究. 结果显示,根据癌症类型和突变,疗效不同,突出显示了向治疗的潜力.
科学领域:
- 癌症学
- 遗传学
- 药理学
背景情况:
- 在许多癌症类型中,ERBB2 (HER2) 和ERBB3 (HER3) 的体质突变很普遍.
- 虽然已知一些突变会导致构成性HER2激活,但大多数突变的生物学意义仍未确定.
- 临床前模型对HER2和HER3突变生物学全谱的洞察力有限.
研究的目的:
- 确定已知和未知的瘤HER2和HER3突变的生物学和治疗重要性.
- 在基因组选择的患者队列中评估泛HER激酶抑制剂内拉替尼的疗效.
- 将临床结果与特定的瘤类型和HER2/HER3突变特征相关联.
主要方法:
- 使用尼拉替尼进行了多组织学"篮子"临床试验 (SUMMIT;NCT01953926).
- 纳入具有ERBB2或ERBB3突变的癌症患者.
- 根据瘤组织学和特定突变特征分析治疗反应.
主要成果:
- 在不同癌症类型和特定的HER2/ HER3突变中,内拉替尼的疗效有显著差异.
- 乳腺癌,子宫癌和胆道癌的治疗活性最高.
- 具有酶域误解突变的瘤表现出显著的反应.
结论:
- 分子驱动的篮子试验对于阐明遗传变化的生物学作用至关重要.
- 在特定的HER2突变癌症中,特别是那些具有误解突变的癌症中,内拉替尼是有前途的.
- 这种方法促进了基因组驱动瘤学的理解和应用.
更多相关视频
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
13.1K
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
1.8K
相关概念视频
Protein Kinases and Phosphatases
15.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.2K
Protein Kinases and Phosphatases
4.5K
4.5K
Feedback Inhibition
57.4K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.4K
Receptor Tyrosine Kinases
19.4K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
19.4K
Enzyme Inhibition
92.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.9K
Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
